The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

The approval is based on a multi-center, randomized, double-blind, placebo-controlled phase III study to confirm the efficacy and safety of Stapokibart injection in treatment of adult patients with ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

Despite the recently reported national decline in opioid overdose deaths, many U.S. communities, including New Orleans, continue to see an ...

The FDA has accepted for review the NDA for bumetanide nasal spray for edema associated with CHF, as well as hepatic and renal disease.

Keymed Biosciences (HKEX: 02162) today announced the National Medical Products Administration (the "NMPA") of China has recently approved the supplemental ...

Mumbai: Global pharma major Lupin Limited has announced that it has received approval from the United States Food and Drug ...

In the study, scientists used a spray. Nasal vestibulitis is not usually ... or a sinus infection. With prompt medical treatment, the infection can improve in just a few days.